Werewolf Therapeutics, Inc.
HOWL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HOWL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HOWL
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing engineered cytokine therapies (INDUKINE molecules) based on its PREDATOR platform, with lead candidates WTX-124 and WTX-330 in early clinical trials. The company is currently undergoing a strategic review to maximize stockholder value and has no approved products or product revenue.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$45.8M
Cash Runway
—
Lead Asset
wtx-1011 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 3 clinical trials for Werewolf Therapeutics, Inc..
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing engineered cytokine therapies (INDUKINE molecules) based on its PREDATOR platform, with lead candidates WTX-124 and WTX-330 in early clinical trials. The company is currently undergoing a strategic review to maximize stockholder value and has no approved products or product revenue.
- Werewolf Therapeutics is focused on developing its PREDATOR platform to create INDUKINE molecules, with lead candidates WTX-124 and WTX-330 in early clinical trials [sec_mda · as of 2026-03-27].
- The company is currently conducting a strategic review to explore alternatives to maximize stockholder value, which will inform future funding requirements [sec_mda · as of 2026-07-31].
- As of 2026-06-30, the company reported cash and equivalents of $22.0M, net income of $3.7M, and shareholders' equity of $41.5M [sec].
- Werewolf has no product revenue and expects to continue incurring substantial net losses for the foreseeable future [sec_mda · as of 2025-11-04].
- All programs beyond WTX-124 and WTX-330 are in discovery or preclinical stages and may never advance to clinical development [sec_mda · as of 2026-03-27].
What works
- The company has a proprietary PREDATOR platform designed to engineer conditionally activated cytokines, which may offer a differentiated approach in immuno-oncology [sec_mda · as of 2026-03-27].
- Werewolf has two product candidates, WTX-124 and WTX-330, that have advanced into clinical trials, indicating some progress in development [sec_mda · as of 2026-07-31].
- As of 2026-06-30, the company reported positive net income of $3.7M and shareholders' equity of $41.5M, suggesting a period of financial stability [sec].
What to weigh
- Werewolf has no approved products and no product revenue, and its ability to generate future revenue is highly uncertain [sec_mda · as of 2026-03-27].
- The company is early in development; all programs beyond WTX-124 and WTX-330 are in preclinical stages and may never reach clinical trials [sec_mda · as of 2026-03-27].
- The ongoing strategic review introduces significant uncertainty regarding the company's future direction, funding, and operating plans [sec_mda · as of 2026-07-31].
- Werewolf expects to continue incurring substantial net losses for the foreseeable future, and cannot estimate the costs to complete development of its candidates [sec_mda · as of 2025-11-04].
From the filings
Quoted directly from source documents.
The company is conducting a strategic review to maximize stockholder value.
“development pipeline to maximize stockholder value. The outcome of our strategic review process will inform our future funding requirements”
SEC MD&A · July 31, 2026
Werewolf has no product revenue and may never develop a marketable product.
“We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.”
SEC MD&A · March 27, 2026
The company's approach is unproven and only two candidates are in clinical development.
“Our approach to the discovery and development of product candidates based on our PREDATOR platform is unproven, and we do not know whether we will be able to develop any approved products of commercial value. In addition, we currently only have two product candidates that we are developing independently, WTX-124 and WTX-330”
SEC MD&A · March 27, 2026
Werewolf expects to continue incurring substantial net losses.
“We expect to continue to incur substantial and increasing expenses and net losses for the foreseeable future”
SEC MD&A · November 4, 2025
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Werewolf has no product revenue and may never develop a commercial product; its ability to generate revenue is highly uncertain [sec_mda · as of 2026-03-27].
- Strategic review uncertainty — The ongoing strategic review creates uncertainty about the company's future direction, funding, and operating plans [sec_mda · as of 2026-07-31].
- Early-stage pipeline — Only two candidates are in clinical trials; all other programs are preclinical and may never advance [sec_mda · as of 2026-03-27].
- Unproven platform technology — The PREDATOR platform is unproven, and the company does not know if it can develop approved products of commercial value [sec_mda · as of 2026-03-27].
What to watch
- Outcome of the strategic review process, which will inform the company's future funding and operational direction [sec_mda · as of 2026-07-31].
- Clinical trial progress and data readouts for WTX-124 and WTX-330 [sec_mda · as of 2026-07-31].
- Changes in cash position and operating expenses as the company navigates the strategic review [sec_mda · as of 2026-07-31].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Werewolf Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Werewolf Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.48 · 0% dilution
Lead: Phase 1
7 candidates
No upcoming catalysts tracked
0 buys · 52 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$11.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 6,681,307 | $5.6M |
| vanguard capital management llc | 2,435,952 | $2.0M |
| mpm bioimpact llc | 1,208,810 | $1.0M |
| lynx1 capital management lp | 657,786 | $548K |
| sphera funds management ltd. | 626,810 | $522K |
| renaissance technologies llc | 516,218 | $430K |
| geode capital management, llc | 389,487 | $324K |
| bank of america corp /de/ | 264,583 | $220K |
| vanguard fiduciary trust co | 157,726 | $131K |
| millennium management llc | 132,050 | $110K |
Showing top 10 of 46 institutional holders of Werewolf Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 3.4%
- Days to cover
- 3.9
- Shares short
- 1,383,049
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HOWL short interestFrequently asked questions
What is the AI investment thesis for Werewolf Therapeutics, Inc.?
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing engineered cytokine therapies (INDUKINE molecules) based on its PREDATOR platform, with lead candidates WTX-124 and WTX-330 in early clinical trials. The company is currently undergoing a strategic review to maximize stockholder value and has no approved products or product revenue.
What is Werewolf Therapeutics, Inc.'s lead drug candidate?
Werewolf Therapeutics, Inc.'s most advanced tracked candidate is wtx-1011 (Preclinical) for cancer.
Who is the CEO of Werewolf Therapeutics, Inc.?
Dr. Daniel J. Hicklin Ph.D. is the chief executive officer of Werewolf Therapeutics, Inc. (HOWL).
Where is Werewolf Therapeutics, Inc. headquartered?
Werewolf Therapeutics, Inc. (HOWL) is headquartered in Watertown, MA, United States.
What therapeutic areas does Werewolf Therapeutics, Inc. focus on?
Werewolf Therapeutics, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.